Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Daniela Matarrese, Massimo Edoardo Di Natale, Pamela Lotti, Donatella Aquilini, Giancarlo Landini, Barbara Cimolato, Massimo Antonio Di Pietro, Michele Trezzi, Paolo Stobbione, Gabriele Frausini, Assunta Navarra, Emanuele Nicastri, Giovanni Sotgiu, Delia Goletti

Research output: Contribution to journalLetter

Original languageEnglish
JournalJournal of Infection
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • Baricitinib
  • COVID-19
  • JAK1/2
  • Pneumonia
  • Retrospective study
  • SARS-Co-V2

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M. E. D., Lotti, P., Aquilini, D., Landini, G., Cimolato, B., Pietro, M. A. D., Trezzi, M., Stobbione, P., Frausini, G., Navarra, A., Nicastri, E., Sotgiu, G., & Goletti, D. (Accepted/In press). Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. Journal of Infection. https://doi.org/10.1016/j.jinf.2020.06.052